Cargando…

Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan

The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pai...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Masahiko, Kobayashi, Hisanori, Okazaki, Masateru, Imanaka, Keiichiro, Yoshizawa, Kazutake, Mahlich, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131454/
https://www.ncbi.nlm.nih.gov/pubmed/29774804
http://dx.doi.org/10.1177/1557988318776123
_version_ 1783354107781709824
author Nakayama, Masahiko
Kobayashi, Hisanori
Okazaki, Masateru
Imanaka, Keiichiro
Yoshizawa, Kazutake
Mahlich, Jörg
author_facet Nakayama, Masahiko
Kobayashi, Hisanori
Okazaki, Masateru
Imanaka, Keiichiro
Yoshizawa, Kazutake
Mahlich, Jörg
author_sort Nakayama, Masahiko
collection PubMed
description The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute. A total of 103 PCa patients and 127 physicians responded. The study looked at 37 patients considered as advanced PCa and 66 who were non-advanced PCa. All of the physicians were urologists. Advanced PCa patients ranked the attributes as follows: treatment effectiveness (RI: 32%), accessibility of treatment (RI: 26%), QOL (RI: 23%), and side effects (RI: 19%). For physicians, the RI ranking was the same as for advanced PCa patients; treatment effectiveness (RI: 29%), accessibility of treatment (RI: 27%), QOL (RI: 26%), and side effects (RI: 18%). For non-advanced PCa patients, accessibility of treatment ranked the highest RI (27%) and treatment effectiveness ranked as the lowest RI (14%). Our study suggests that the ranking of the attributes was consistent between advanced PCa patients and physicians. The most influential attribute was treatment effectiveness. Treatment preferences also vary by disease stage.
format Online
Article
Text
id pubmed-6131454
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61314542018-09-13 Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan Nakayama, Masahiko Kobayashi, Hisanori Okazaki, Masateru Imanaka, Keiichiro Yoshizawa, Kazutake Mahlich, Jörg Am J Mens Health Original Articles The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute. A total of 103 PCa patients and 127 physicians responded. The study looked at 37 patients considered as advanced PCa and 66 who were non-advanced PCa. All of the physicians were urologists. Advanced PCa patients ranked the attributes as follows: treatment effectiveness (RI: 32%), accessibility of treatment (RI: 26%), QOL (RI: 23%), and side effects (RI: 19%). For physicians, the RI ranking was the same as for advanced PCa patients; treatment effectiveness (RI: 29%), accessibility of treatment (RI: 27%), QOL (RI: 26%), and side effects (RI: 18%). For non-advanced PCa patients, accessibility of treatment ranked the highest RI (27%) and treatment effectiveness ranked as the lowest RI (14%). Our study suggests that the ranking of the attributes was consistent between advanced PCa patients and physicians. The most influential attribute was treatment effectiveness. Treatment preferences also vary by disease stage. SAGE Publications 2018-05-18 2018-07 /pmc/articles/PMC6131454/ /pubmed/29774804 http://dx.doi.org/10.1177/1557988318776123 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Nakayama, Masahiko
Kobayashi, Hisanori
Okazaki, Masateru
Imanaka, Keiichiro
Yoshizawa, Kazutake
Mahlich, Jörg
Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title_full Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title_fullStr Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title_full_unstemmed Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title_short Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
title_sort patient preferences and urologist judgments on prostate cancer therapy in japan
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131454/
https://www.ncbi.nlm.nih.gov/pubmed/29774804
http://dx.doi.org/10.1177/1557988318776123
work_keys_str_mv AT nakayamamasahiko patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan
AT kobayashihisanori patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan
AT okazakimasateru patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan
AT imanakakeiichiro patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan
AT yoshizawakazutake patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan
AT mahlichjorg patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan